SciBase introduces Nevisense View – integrating images in the fight against malignant melanoma

With its new instrument, Nevisense View, SciBase combines its patented
electrical impedance spectroscopy (EIS) for early detection of malignant
melanoma with visual information from digital dermascopy, creating a complete
instrument that can both improve and simplify the diagnostic process.
Malignant melanoma is the most threatening form of skin cancer and is behind 75
percent of all skin cancer deaths. The key to successful treatment of malignant
melanoma is early discovery, since this aggressive form of cancer can quickly
spread throughout the body. The cancer is often difficult to detect, and digital
dermascopy is one of the methods used for detection. This method is based on
visual evaluations of skin lesions using a dermascope, while hard-to-diagnose
cases often make use of short term digital dermoscopy imaging (SDDI) to compare
pictures of lesions that have changed over time.

SciBase is now integrating the digital dermascopy method into its new product
and combining it with EIS technology, which uses electrical impulses to detect
abnormal cell structures that could be a sign of malignant melanoma.
Furthermore, SciBase’s new instrument also simplifies the process for performing
skin examinations since all information from the exam is saved in the same
instrument. The ability to track the changes of a suspicious lesion, both using
EIS values and images, helps prevent both the unnecessary removal of benign
tissue and helps avoid malignant melanoma going undetected during an
examination.

“According to a new study, conducted by researchers from Melanoma Institute of
Australia and Royal Prince Alfred Hospital in Sydney, the use of EIS can reduce
the number of cases that need to be followed up using SDDI by almost half, and
may also allow for early detection of malignant melanoma three months earlier
than traditional methods,” says Simon Grant, CEO of SciBase.

“Being able to combine these two methods into one product and present it in
conjunction with a study that supports our method at the World Congress on
Cancers of the Skin in Vienna on August 31 is of course a milestone in the
company’s history,” says Simon.

Nevisense View simplifies caregivers’ work by offering the following functions:

  · Wireless transfer of images to Nevisense
  · Combination of EIS, image and patient information as a PDF report for full
documentation of the examination.
  · Easy-to-use follow-up functions, such as a shared screen for being able to
compare lesions over time.

Nevisense View will be available in Sweden and in SciBase’s other markets in
November. More information about the study can be found here: Swedish Nevisense
can reduce follow up visits by half for difficult-to-diagnose skin changes in
melanoma detection (http://investors.scibase.se/en/new-study-swedish-nevisense
-can-reduce-follow-up-visits-by-half-for-difficult-to-diagnose-lesions-in)

For more information, please contact:

Simon Grant, CEO
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com

This information is information that SciBase Holding AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information was submitted
for publication, through the agency of the contact person set out above, at
08.00 CET on August 31, 2016.

About Skin Cancer
Skin cancer is one of the most common cancers in the world, accounting for
nearly half of all cancers. It has been estimated that nearly half of all
Americans who live to the age of 65 will develop skin cancer at least once.
Malignant melanoma is the most fatal form of skin cancer causing the majority
(75%) of deaths related to skin cancer. Worldwide, doctors diagnose about
230,000 new cases of melanoma yearly.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.